by
According to the Foreclaro Global Research, the
Global
Cell and Gene Therapy Market size was valued at USD 24905.7 million in 2024.
The report “Global Cell and Gene Therapy Market Segmentation By
Therapy Type (Cell Therapy {Stem Cell Therapy, Non-Stem Cell Therapy}, Gene
Therapy {Gene Editing, Gene Augmentation, Gene Silencing}), By Indication (Oncology
{Leukaemia, Lymphoma, Solid Tumours}, Rare Diseases {Genetic Disorders, Metabolic
Disorders}, Cardiovascular Diseases, Neurological Disorders, Orthopaedic &
Musculoskeletal, Ophthalmology, Infectious Diseases), By Delivery Method (In
Vivo Gene Therapy, Ex Vivo Gene Therapy, In Situ Gene Therapy), By Technology (Viral
Vector Technology, Non-Viral Vector Technology, Genome Editing Platforms, Cell
Reprogramming), By End User (Hospitals & Clinics, Specialty Treatment
Centres, Academic & Research Institutes, Biopharmaceutical Companies, Contract
Development & Manufacturing Organizations (CDMOs)- Industry Trends and Forecast to 2033” gives a detailed insight into
current market dynamics and provides analysis on future market growth.
Cell and gene therapy (CGT) is revolutionizing
contemporary-day treatment through addressing illnesses at their genetic and molecular
roots, presenting the capacity for long-term or recuperation treatments. Cell
treatment plans, collectively with CAR-T and stem mobile approaches, harness
residing cells to restore tissues or right now purpose disease, whilst gene
treatment plans alter or update defective genes the usage of strategies like
CRISPR and viral vectors. Widely carried out in oncology, uncommon genetic
disorders, and regenerative treatment, CGT suggests a shift in the course of
personalized, precision treatment. Rapid technological advances, advanced
regulatory support, and massive investments from biopharmaceutical businesses
and startups have fueled growth, essential to new approvals and developing
pipelines. Despite annoying situations like excessive manufacturing costs,
complicated logistics, and compensation hurdles, global collaborations and
innovation in delivery methods, allogeneic (off-the-shelf) treatment plans, and
scalable production are the usage of broader adoption. Together, CGT is
transforming the healthcare landscape, redefining remedy possibilities, and offering
hope to sufferers with situations formerly deemed untreatable.
Have any questions or need more information?
Click the link below to request a sample or make an inquiry before making your
purchase:
https://foreclaroglobalresearch.com/research-report/global-cell-and-gene-therapy-market
Global Cell
and Gene Therapy Market Report Highlights
· Rapid
marketplace increase pushed with the aid of growing approvals of progressive
treatment plans concentrated on cancers, uncommon genetic disorders, and
persistent diseases.
· Advances
in technology, along with CRISPR gene editing, progressed viral vectors, and
scalable production platforms, boosting performance and precision.
· Expansion
of allogeneic (“off-the-shelf”) and in vivo treatment plans, aiming to lessen
prices and triumph over logistical obstacles related to customized treatments.
· Strong
pipeline activity, with loads of scientific trials exploring new indicators beyond
oncology, which include cardiovascular and neurological diseases.
· Strategic
partnerships and acquisitions among biotech startups and massive pharmaceutical
companies, accelerating research, development, and commercialization.
· Regional
increase led with the aid of using North America and Europe, supported with the
aid of using favorable regulatory pathways, with Asia-Pacific rising speedy
because of growing investments and neighborhood production capabilities.
Foreclaro Global Research has segmented the Cell
and Gene Therapy Market report based on Therapy Type, Indication, Delivery
Method, Technology, End User Industry and region:
Cell and Gene Therapy Market,
Therapy Type Outlook (Revenue - USD Million, 2020 - 2033)
Cell Therapy
·
Stem
Cell Therapy
·
Non-Stem
Cell Therapy
Gene Therapy
·
Gene
Editing
·
Gene
Augmentation
·
Gene
Silencing
Cell and Gene Therapy Market, Indication
Outlook (Revenue - USD Million, 2020 - 2033)
Oncology
·
Leukemia
·
Lymphoma
·
Solid
Tumors
Rare Diseases
·
Genetic
Disorders
·
Metabolic
Disorders
Cardiovascular Diseases
Neurological Disorders
Orthopedic & Musculoskeletal
Ophthalmology
Infectious Diseases
Cell and Gene Therapy Market, Delivery
Method Outlook (Revenue - USD Million, 2020 - 2033)
In Vivo Gene Therapy
Ex Vivo Gene Therapy
In Situ Gene Therapy
Cell and Gene Therapy Market, Technology
Outlook (Revenue - USD Million, 2020 - 2033)
Viral Vector Technology
Non-Viral Vector Technology
Genome Editing Platforms
Cell Reprogramming
Cell and Gene Therapy Market, End
User Outlook (Revenue - USD Million, 2020 - 2033)
Hospitals & Clinics
Specialty Treatment Centers
Academic & Research Institutes
Biopharmaceutical Companies
Contract Development &
Manufacturing Organizations (CDMOs)
Cell and Gene Therapy Market,
Regional Outlook (Revenue - USD Million, 2020 - 2033)
North America
·
United
States
·
Canada
·
Mexico
Europe
·
United
Kingdom
·
Germany
·
France
·
Spain
·
Italy
·
Rest
of Europe
Asia Pacific
·
China
·
India
·
Japan
·
Australia
·
South
Korea
·
Rest
of Asia Pacific
Latin America
·
Brazil
·
Argentina
·
Rest
of Latin America
Middle East & Africa
·
Saudi
Arabia
·
South
Africa
·
Rest
of MEA
Global Cell and Gene Therapy
Market Key Players
·
Samsung
·
Sony Corporation
·
Thales Group
·
Block, Inc.
·
CardLogix Corporation
·
CPI Card Group Inc.
·
Giesecke+Devrient GmbH
·
HID Global Corporation
·
IDEMIA
·
INTELIGENSA
